Bioresorbable vascular scaffold: a step back thinking of the future.
作者信息
Polimeni Alberto, Gori Tommaso
机构信息
Kardiologie I, Zentrum für Kardiologie, University Medical Center Mainz and DZHK standort Rhein-Main, Mainz, Germany.
Division of Cardiology, Department of Medical and Surgical Sciences, "Magna Graecia" University, Catanzaro, Italy.
出版信息
Postepy Kardiol Interwencyjnej. 2018;14(2):117-119. doi: 10.5114/aic.2018.76401. Epub 2018 Jun 19.
Abstract
摘要
相似文献
1
Bioresorbable vascular scaffold: a step back thinking of the future.生物可吸收血管支架：对未来的逆向思考。
Postepy Kardiol Interwencyjnej. 2018;14(2):117-119. doi: 10.5114/aic.2018.76401. Epub 2018 Jun 19.
2
Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Microfiber Sirolimus-Eluting Scaffold Using Multimodality Imaging.随机比较 Absorb 生物可吸收血管支架和 Mirage 微纤维西罗莫司洗脱支架的多模式影像学研究。
JACC Cardiovasc Interv. 2017 Jun 12;10(11):1115-1130. doi: 10.1016/j.jcin.2017.03.015. Epub 2017 May 17.
3
Two-year follow-up of bioresorbable vascular scaffolds in severe infra-popliteal arterial disease.严重下肢动脉疾病中生物可吸收血管支架的两年随访。
Vascular. 2021 Jun;29(3):355-362. doi: 10.1177/1708538120954947. Epub 2020 Sep 14.
4
Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.对比依维莫司洗脱生物可吸收支架与依维莫司洗脱金属支架治疗冠状动脉狭窄的疗效（ABSORB II）：3 年随机、对照、单盲、多中心临床试验。
Lancet. 2016 Nov 19;388(10059):2479-2491. doi: 10.1016/S0140-6736(16)32050-5. Epub 2016 Oct 30.
5
Vascular restoration therapy and bioresorbable vascular scaffold.血管修复治疗和生物可吸收血管支架。
Regen Biomater. 2014 Nov;1(1):49-55. doi: 10.1093/rb/rbu005. Epub 2014 Oct 20.
6
Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.依维莫司洗脱生物可吸收血管支架与依维莫司洗脱金属支架的比较：随机对照试验的荟萃分析。
Lancet. 2016 Feb 6;387(10018):537-544. doi: 10.1016/S0140-6736(15)00979-4. Epub 2015 Nov 17.
7
A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.生物可吸收依维莫司洗脱支架与金属依维莫司洗脱支架治疗初发原生冠状动脉病变所致缺血性心脏病的比较（ABSORB II）：一项随机对照临床试验的临床和操作次要终点 1 年中期分析。
Lancet. 2015 Jan 3;385(9962):43-54. doi: 10.1016/S0140-6736(14)61455-0. Epub 2014 Sep 14.
8
Mechanical properties and degradation of drug eluted bioresorbable vascular scaffolds prepared by three-dimensional printing technology.采用三维打印技术制备的药物洗脱生物可吸收血管支架的力学性能及降解
J Biomater Sci Polym Ed. 2019 May;30(7):547-560. doi: 10.1080/09205063.2019.1586303. Epub 2019 Apr 7.
9
Is the Dream of Vascular Restoration Still Alive? A Case of 7 Years, Follow-Up After Bioresorbable Vascular Scaffold Implantation.血管修复的梦想是否依然存在？生物可吸收血管支架置入后 7 年的随访病例
Cardiovasc Revasc Med. 2020 Nov;21(11S):158-161. doi: 10.1016/j.carrev.2019.12.034. Epub 2020 Jan 7.
10
The Absorb bioresorbable vascular scaffold for the treatment of coronary artery disease.
Expert Opin Drug Deliv. 2016 Oct;13(10):1489-99. doi: 10.1080/17425247.2016.1227788. Epub 2016 Sep 7.
引用本文的文献
1
Procedural Predictors for Bioresorbable Vascular Scaffold Thrombosis: Analysis of the Individual Components of the "PSP" Technique.生物可吸收血管支架血栓形成的手术预测因素：“PSP”技术各组成部分的分析
J Clin Med. 2019 Jan 15;8(1):93. doi: 10.3390/jcm8010093.
本文引用的文献
1
Comparison of the Absorb bioresorbable vascular scaffold to the Xience durable polymer everolimus-eluting metallic stent in routine clinical practice: a propensity score-matched analysis from a multicenter registry.在常规临床实践中比较Absorb生物可吸收血管支架与Xience耐用聚合物依维莫司洗脱金属支架：一项来自多中心注册研究的倾向评分匹配分析。
Postepy Kardiol Interwencyjnej. 2018;14(2):149-156. doi: 10.5114/aic.2018.76406. Epub 2018 Jun 19.
2
Two-year clinical outcomes after implantation of an everolimus-eluting bioresorbable scaffold (Absorb) in stable angina and acute coronary syndrome patients. Single-centre real-life registry data.在稳定性心绞痛和急性冠状动脉综合征患者中植入依维莫司洗脱生物可吸收支架（Absorb）后的两年临床结果。单中心真实世界注册数据。
Postepy Kardiol Interwencyjnej. 2018;14(2):144-148. doi: 10.5114/aic.2018.76405. Epub 2018 Jun 19.
3
Three-years outcomes of diabetic patients treated with coronary bioresorbable scaffolds.接受冠状动脉生物可吸收支架治疗的糖尿病患者的三年随访结果
BMC Cardiovasc Disord. 2018 May 10;18(1):92. doi: 10.1186/s12872-018-0811-7.
4
Bioresorbable everolimus-eluting vascular scaffold for patients presenting with non STelevation-acute coronary syndrome: A three-years follow-up1.用于非ST段抬高型急性冠状动脉综合征患者的生物可吸收依维莫司洗脱血管支架：三年随访1
Clin Hemorheol Microcirc. 2018;69(1-2):3-8. doi: 10.3233/CH-189101.
5
Characteristics, Predictors, and Mechanisms of Thrombosis in Coronary Bioresorbable Scaffolds: Differences Between Early and Late Events.冠状动脉生物可吸收支架内血栓形成的特征、预测因素和机制：早期和晚期事件的差异。
JACC Cardiovasc Interv. 2017 Dec 11;10(23):2363-2371. doi: 10.1016/j.jcin.2017.08.020.
6
Characteristics and outcome of patients with complex coronary lesions treated with bioresorbable scaffolds: three-year follow-up in a cohort of consecutive patients.生物可吸收支架治疗复杂冠状动脉病变患者的特点和结局：连续患者队列的三年随访结果。
EuroIntervention. 2018 Oct 12;14(9):e1011-e1019. doi: 10.4244/EIJ-D-17-00410.
7
Incidence, Clinical Presentation, and Predictors of Clinical Restenosis in Coronary Bioresorbable Scaffolds.生物可吸收支架冠状动脉临床再狭窄的发生率、临床表现及预测因素。
JACC Cardiovasc Interv. 2017 Sep 25;10(18):1819-1827. doi: 10.1016/j.jcin.2017.07.034.
8
Long-term outcome of bioresorbable vascular scaffolds for the treatment of coronary artery disease: a meta-analysis of RCTs.生物可吸收血管支架治疗冠状动脉疾病的长期疗效：随机对照试验的荟萃分析
BMC Cardiovasc Disord. 2017 Jun 7;17(1):147. doi: 10.1186/s12872-017-0586-2.
9
Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents.依维莫司洗脱生物可吸收支架与依维莫司洗脱金属支架比较
J Am Coll Cardiol. 2017 Jun 27;69(25):3055-3066. doi: 10.1016/j.jacc.2017.04.011. Epub 2017 Apr 12.
10
Bioresorbable Scaffolds versus Metallic Stents in Routine PCI.生物可吸收支架与金属支架在常规 PCI 中的应用比较。
N Engl J Med. 2017 Jun 15;376(24):2319-2328. doi: 10.1056/NEJMoa1614954. Epub 2017 Mar 29.
Zotero 插件